Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02590874 · ClinicalTrials.gov registry record · Phase 4
The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment
A Phase 4 study, sponsored by University of North Texas Health Science Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT02590874 is a Phase 4 study that has completed, run by University of North Texas Health Science Center. The registered enrollment target is 19 participants.
The verdict
NCT02590874, a Phase 4 study, has completed, sponsored by University of North Texas Health Science Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Cymbalta (duloxetine) is effective to improve cognition in individuals with Mild Cognitive Impairment.
Interventions
- DRUG Placebo
- DRUG Duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-01 |
| Est. Completion | 2018-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02590874
The ClinicalTrials.gov registry entry for NCT02590874 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Texas Health Science Center, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02590874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02590874 about?
NCT02590874 is a clinical study titled "The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment". The purpose of this study is to determine whether Cymbalta (duloxetine) is effective to improve cognition in individuals with Mild Cognitive Impairment.
What is the current status of trial NCT02590874?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2016-01. Estimated completion is 2018-10.
What interventions are being tested in trial NCT02590874?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG).
Who is sponsoring clinical trial NCT02590874?
This trial is sponsored by University of North Texas Health Science Center, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.